(Q39255639)

English

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

8

object named as

George W Sledge

1 reference

Europe PubMed Central

10 September 2017

author name string

Yesim Gökmen-Polar

1

1 reference

Europe PubMed Central

10 September 2017

Yi Liu

2

1 reference

Europe PubMed Central

10 September 2017

Rachel A Toroni

3

1 reference

Europe PubMed Central

10 September 2017

Kerry L Sanders

4

1 reference

Europe PubMed Central

10 September 2017

Rutika Mehta

5

1 reference

Europe PubMed Central

10 September 2017

Sunil Badve

6

1 reference

Europe PubMed Central

10 September 2017

Christian Rommel

7

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

21 October 2012

1 reference

Europe PubMed Central

10 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

10 September 2017

136

1 reference

Europe PubMed Central

10 September 2017

673-682

1 reference

Europe PubMed Central

10 September 2017

3

1 reference

Europe PubMed Central

10 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-012-2298-8

0 references

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An emerging role of mTOR in lipid biosynthesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

eIF-4E expression and its role in malignancies and metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

The translational landscape of mTOR signalling steers cancer initiation and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

All roads lead to mTOR: integrating inflammation and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2298-8

21 January 2018

Identifiers

10.1007/S10549-012-2298-8

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39255639&oldid=1816044099"